ResearchRSS2 days ago
Scientists used artificial intelligence to analyze medical records from hundreds of PAH patients and created a new tool that can predict whether a patient's condition will get worse in the future. PAH is a serious lung disease where blood vessels in the lungs become narrowed, making it hard for the heart to pump blood. This new AI system could help doctors catch problems earlier and adjust treatment plans before patients get sicker.
WHY IT MATTERSIf this AI tool becomes available in clinical practice, PAH patients could receive earlier warning signs of disease worsening, allowing doctors to intensify treatment before serious complications develop.
ResearchRSS4 days ago
Researchers in China used artificial intelligence to study the genes involved in pulmonary arterial hypertension (PAH), a serious condition where blood vessels in the lungs become narrowed and stiff. They identified two genes called ATP1B1 and HP that appear to be important in causing PAH. These genes could potentially become targets for new treatments in the future.
WHY IT MATTERSIf ATP1B1 and HP prove to be valid therapeutic targets, they could lead to new treatment options for PAH patients who currently have limited medication choices.
ResearchRSSMay 6
Scientists in China discovered four genes—COL1A1, MYL9, COL1A2, and TPM2—that may be responsible for causing idiopathic pulmonary arterial hypertension (PAH), a rare lung disease where blood vessels in the lungs become abnormally narrow and stiff. They used computer analysis to identify these genes and then tested their findings in cells and animals to confirm the results. These genes could become targets for new treatments in the future.
WHY IT MATTERSIdentifying these four driver genes gives researchers specific targets to develop new treatments for idiopathic PAH, a disease with limited treatment options and poor survival rates if left untreated.
ResearchRSSMay 4
Researchers in China created a new drug called CPD1 that belongs to a class of medications called PDE5 inhibitors, which are already used to treat high blood pressure in the lungs (pulmonary arterial hypertension). In early testing on rats with this condition, CPD1 reduced disease severity and helped scientists understand how the drug works at a molecular level.
WHY IT MATTERSThis research identifies a potential new treatment option for PAH patients, though it remains in early preclinical stages and is years away from human testing or availability.
ResearchRSSApr 27
A new study found that people with pulmonary arterial hypertension (PAH), a rare lung disease, often develop irregular heartbeats like atrial fibrillation and atrial flutter. These irregular heartbeats, where the heart beats too fast or out of sync, were linked to worse health outcomes in PAH patients. This research helps doctors understand an important complication that affects many people living with PAH.
WHY IT MATTERSIf you have PAH, knowing that irregular heartbeats are common and linked to higher risks means you should ask your doctor about screening for arrhythmias and what symptoms to watch for.